Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Compass Therapeutics Inc (NASDAQ: CMPX) closed at $3.67 down -0.81% from its previous closing price of $3.7. In other words, the price has decreased by -$0.81 from its previous closing price. On the day, 2.12 million shares were traded. CMPX stock price reached its highest trading level at $3.8 during the session, while it also had its lowest trading level at $3.47.
Ratios:
For a deeper understanding of Compass Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.66 and its Current Ratio is at 7.66. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
On April 02, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $6.
On February 24, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $12.Guggenheim initiated its Buy rating on February 24, 2025, with a $12 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 27 ’25 when Schuetz Thomas J. bought 10,000 shares for $2.11 per share. The transaction valued at 21,100 led to the insider holds 6,480,825 shares of the business.
GORDON CARL L sold 3,571,428 shares of CMPX for $5,678,571 on Apr 09 ’25. The Director now owns 0 shares after completing the transaction at $1.59 per share. On Apr 09 ’25, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 3,571,428 shares for $1.59 each. As a result, the insider received 5,678,571 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CMPX now has a Market Capitalization of 629671104 and an Enterprise Value of 416451776.
Stock Price History:
The Beta on a monthly basis for CMPX is 1.29, which has changed by 1.1213872 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, CMPX has reached a high of $4.08, while it has fallen to a 52-week low of $1.27. The 50-Day Moving Average of the stock is 12.03%, while the 200-Day Moving Average is calculated to be 41.60%.
Shares Statistics:
For the past three months, CMPX has traded an average of 1.24M shares per day and 1697420 over the past ten days. A total of 138.28M shares are outstanding, with a floating share count of 109.99M. Insiders hold about 35.89% of the company’s shares, while institutions hold 43.14% stake in the company. Shares short for CMPX as of 1757894400 were 12141511 with a Short Ratio of 9.78, compared to 1755216000 on 9525164. Therefore, it implies a Short% of Shares Outstanding of 12141511 and a Short% of Float of 11.4300005.
Earnings Estimates
The market rating of Compass Therapeutics Inc (CMPX) is currently shaped by the ongoing analysis conducted by 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.04 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.4 and -$0.6 for the fiscal current year, implying an average EPS of -$0.54. EPS for the following year is -$0.55, with 8.0 analysts recommending between -$0.25 and -$0.76.
